Verification evidence is still being completed.
PDF / print export
Xintela
Lund, Sweden
- Verified lead
- Evy Lundgren-Akerlund
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Stem Cell Therapy, ATMP Manufacturing, Regenerative Medicine, Targeted Oncology, and Clinical Development
- Review cycle
- May 2026
- Full address
- Xintela AB, Medicon Village, Scheeletorget 1, Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Xintela contact section confirming the Lund operating address.
- Editorial note
- Xintela is published because official company materials confirm current leadership, Lund operating address, and a real regenerative-medicine and targeted-cancer platform.
Stem Cell Therapy, ATMP Manufacturing, Regenerative Medicine, Targeted Oncology, and Clinical Development
Official leadership disclosure, Official Lund address disclosure, ATMP and GMP platform disclosure
Xintela is published because official company materials confirm current leadership, Lund operating address, and a real regenerative-medicine and targeted-cancer platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Xintela
Stem Cell Therapy, ATMP Manufacturing, Regenerative Medicine, Targeted Oncology, and Clinical Development · Clinical-stage cell-therapy platform
Xintela runs stem cell therapeutics, targeted cancer programs, and atmp manufacturing in Lund, Sweden.
- Lead
- Evy Lundgren-Akerlund (verified ↗)
- Address
- Xintela AB, Medicon Village, Scheeletorget 1, Lund, Sweden (source ↗)
- Compliance
- ATMP and GMP platform disclosure
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage cell-therapy platform
- Capabilities
- Stem Cell Therapeutics · Targeted Cancer Programs · ATMP Manufacturing
- Founded
- 2009
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Evy Lundgren-Akerlund
Chief Executive Officer
Full addressXintela AB, Medicon Village, Scheeletorget 1, Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Xintela contact section listing the Lund Medicon Village address.
Open sourceClinical-stage cell-therapy platform
Lund, Sweden. Stem Cell Therapy, ATMP Manufacturing, Regenerative Medicine, Targeted Oncology, and Clinical Development. Review completed on 21 Mar 2026.
Swedish corporate, advanced-therapy, and clinical-development oversight
Official leadership disclosure, Official Lund address disclosure, ATMP and GMP platform disclosure
Stem Cell Therapy, ATMP Manufacturing, Regenerative Medicine, Targeted Oncology, and Clinical Development
Xintela is published because official company materials confirm current leadership, Lund operating address, and a real regenerative-medicine and targeted-cancer platform.
Editorial note
Xintela is published because official company materials confirm current leadership, Lund operating address, and a real regenerative-medicine and targeted-cancer platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Stem Cell Therapeutics
Targeted Cancer Programs
ATMP Manufacturing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Stem-cell development workflow
ATMP manufacturing systems
Clinical development infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Xintela located?
- Xintela operates from Xintela AB, Medicon Village, Scheeletorget 1, Lund, Sweden, Lund, Sweden.
- Who runs Xintela?
- Xintela is led by Evy Lundgren-Akerlund, Chief Executive Officer. Verified 21 Mar 2026.
- What certifications does Xintela hold?
- Xintela is documented under ATMP and GMP platform disclosure.
- What does Xintela do?
- Xintela runs stem cell therapeutics, targeted cancer programs, and atmp manufacturing in Lund, Sweden. Core capabilities: Stem Cell Therapeutics, Targeted Cancer Programs, ATMP Manufacturing.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.